Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, that's all and good but John needs to be more of a talker as well as a doer!
This is one of the worst performing MJ stocks out there, and I along with other shareholders feel that we're being treated like mushrooms, kept in the dark and fed shit, it shouldn't be necessary for every shareholder to phone the company in an effort to find out what the hell is going on and what he's doing to turn this ship around!
Good communication is an important leadership skill!
Bio- Chief Legal Officer and Senior Vice President of Innovation Dr. Ergenzinger
https://www.mediate.com/author/Edward-R.-Ergenzinger,-Jr./406
Remember they have sold 34% of this project to another entity, plus 10% of cannabis sales go to LSU.
Tax loss selling is underway!
CNN Article GB Sciences and LSU
https://www.cnn.com/2018/11/27/health/louisiana-medical-marijuana/index.html
A lot of the money, I assume, has gone into the Louisiana project, from which we haven't seen any income because of government incompetence, Jan should see a big jump in revenues barring any more gov't delays.
I'd like to know what's happening with the expansion of the Nevada Teco grow, this expansion was supposed to be their #1 priority.
The company needs to do a lot better with their communication to shareholders. That's part of the reason GB Sciences is one of the worst performing pot stocks out there!!
Yes, the government there seem like idiots, they could have sent the cannabis out of state for testing, at least until they had a lab up and running. Poor planning to say the least!
Should have another crop harvested before January, so GB should have strong sales starting in January, especially with the other producer all screwed up. The concentrates GB is producing are all high margin, value-added products also.
Looks like GB Sciences will be the only supplier for a while!
Still no testing! Probably no sales till next year.
https://www.nola.com/expo/news/erry-2018/11/4d0e2f42465852/what-to-know-about-louisianas.html
Does anyone know what's happening in Louisiana? Last I heard the government couldn't find a lab to test the cannabis, has this been resolved? When are sales projected to begin?
What is TECO? TIA.
Pivot Pharma/ERS Holdings Patents Pending
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=ERS+holdings&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PG01
Basically they are using Maltodextrin as an emulsifier for the Cannabis oils, claims to be tasteless and dissolves in hot or cold beverages, or can be used to produce edibles.
Maltodextrin not exactly a health food
"Maltodextrin and diabetes
Maltodextrin has an even higher glycemic index (GI) than table sugar. This means that maltodextrin can cause a sharp increase, or spike, in people's blood sugar shortly after they eat foods that contain it.
A spike in blood glucose can be particularly dangerous for people with diabetes or insulin resistance."
https://www.medicalnewstoday.com/articles/322426.php
Competition- Pivot Pharma- https://equity.guru/microposts/pivot-pharma-acquires-ers-cannabis-tech/
"They range from a joint application filed in 2011 by British, Italian and Spanish scientists on how phytocannabinoids — a component of the cannabis plant — can be used in the treatment of cancer, to a more recent application from American researchers who claim to have found a method to make concentrated cannabis oil “stable, emulsifiable and flavourless” so it can be used in hot beverages."
https://business.financialpost.com/cannabis/cannabis-companies-race-to-clinch-an-edge-in-pot-industrys-next-phase-of-growth-intellectual-property?fbclid=IwAR2jmUlAckO_P-o3udGy8aNMTeMTYdHyYJY46u-nxQO98GWffkBLsWBRpjI
Yes, they need to get everyone buzzed and then implant subliminal messages to buy LXRP/LXX shares.
Why do they have a product launch with only CBD and no THC. I'm sure it's coming though!
Just looking through the recent annual report and I couldn't find any reference to any ongoing research with the National Research Council of Canada or that there ever was an agreement. All reference to the NRC has disappeared including from the latest investor presentation, the previous presentation sported the logo of the NRC as a research partner.
This can only mean one thing, the NRC has dropped this program!
Unfortunate to say the least.
17 Block Trades
Time ET Ex Symbol Price Change Volume $Value
14:12:47 Q GBLX 0.2249 -0.0001 2,274,200 511,467
12:05:51 Q GBLX 0.22 -0.005 1,321,689 290,771
15:49:12 Q GBLX 0.225 1,241,447 279,325
12:13:36 Q GBLX 0.22 -0.005 758,800 166,936
12:18:39 Q GBLX 0.22 -0.005 726,800 159,896
13:07:04 Q GBLX 0.22 -0.005 422,529 92,956
13:15:03 Q GBLX 0.22 -0.005 407,500 89,650
12:34:34 Q GBLX 0.219 -0.006 349,669 76,577
13:57:11 Q GBLX 0.22 -0.005 290,000 63,800
13:24:43 Q GBLX 0.22 -0.005 189,697 41,733
13:31:57 Q GBLX 0.22 -0.005 150,000 33,000
14:37:27 Q GBLX 0.219 -0.006 150,657 32,993
13:49:54 Q GBLX 0.22 -0.005 140,000 30,800
13:51:07 Q GBLX 0.22 -0.005 130,000 28,600
13:03:22 Q GBLX 0.22 -0.005 124,636 27,419
14:40:41 Q GBLX 0.219 -0.006 108,500 23,761
10:12:31 Q GBLX 0.22 -0.005 103,039 22,668
There's only been one day we traded this many shares, last Jan. we did over 15 million during the big run-up.
Totally agree also.
This new product opens up so many questions. Such as why was it released in only CBD format and not THC. I'm assuming the answer is because they have parties that are interested in licensing the THC product. There are so many SKU possibilities with THC such as THC:CBD 1:1; 1:0 and 8:1 and then different SKUs for different strains White Widow 1:0; OG Kush 1:1; Indica; Sativa and on and on. First movers on this one are going to have a huge advantage.
I think it's clear they're still pursuing the out-licensing format.
"Lexaria's ChrgD+ product format is being evaluated by others for use in their psychoactive cannabinoids products sector as per our proven track record as a technology provider to the industry."
I'm no longer bi-polar on this stock. ChargD+ is going to be a real disruptor. IMHO
GB Sciences Expands into the Oklahoma Medical Cannabis Market
PR Newswire
LAS VEGAS, Nov. 14, 2018
GB Sciences' signs a letter of binding agreement with 4EVERGRN in its first out-of-state licensing deal.
LAS VEGAS, Nov. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is proud to announce that it has signed a binding letter of intent with 4EVERGRN, LLC in Oklahoma. This company has been awarded cultivation, processing and dispensary licenses by the Oklahoma Medical Marijuana Authority.
Under their agreement, GB Sciences will design a cultivation and processing facility in Oklahoma, and provide 4EVERGRN with best-practice operating procedures. 4EVERGRN will produce and distribute GB Sciences products and brands under a licensing agreement in exchange for a royalty to GB Sciences. The agreement can be terminated if quality standards are abridged or compromised.
Monica Poss, VP of Corporate Planning, GB Sciences, remarks: "We are very excited to have penned our first licensing deal and hope it serves as a template for further agreements. These will allow GB Sciences to expand its reach nationwide without extensive capital outlays. Our partners in Oklahoma, Brooklyn Green Clopton and her associates at 4EVERGRN, are serio us and professional in their efforts to bring the advantages of medical cannabis to the people of the state of Oklahoma. We are proud to be partnered with them."
Brooklyn Green Clopton, CEO of 4EVERGRN, responds: "Our 4EVERGRN team is comprised of Oklahomans that are passionate about cutting-edge cannabis development. 4EVERGRN's Dr. JoAnn Ryan has led the charge to ensure we create the best pharmaceutical grade cannabis products for the patients of Oklahoma. We believe GB Sciences' tissue culture propagation will lead the industry with the safest and most consistent products and 4EVERGRN is excited to be partnered with them in Oklahoma's new medical marijuana market."
John Poss, CEO and Chairman of the Board, comments: "Monica has done an excellent job in creating a path to bring our quality plant-based medical cannabis to the folks living outside of the state of Nevada and thereby improving the lives of patients."
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
About 4EVERGRN
4EVERGRN will supply medicinal cannabis products, which have been researched and tested for quality and consistency, to all Oklahoma dispensaries. 4EVERGN's vision is to be a part of a larger movement of Oklahomans who are serious about the use of science-based medical cannabis treatme nt options. This will improve the quality of life for patients, families and communities. We believe that education and the medical use of cannabis will bring healing, alleviate suffering, lower opioid and prescription drug usage, and ultimately empower Oklahomans.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indica ted in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Tom Arcuragi, EVP, tom@gbsciences.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/gb-sciences-expands-into-the-oklahoma-medical-cannabis-market-300749815.html
SOURCE GB Sciences, Inc.
Big volume on Tuesday with most of the volume in 3 trades which happened in the space of 4 min. with 4,495,000 shares trading hands.
Yes, the more one thinks about it, the more brilliantly disruptive this could be. Why buy 6 cannabis-infused beers or pop or some other drink you may not even care for, you buy six packs of ChargD+. Susie puts hers in her wine, Joe puts his in his beer, Al puts his in his tea etc.
Probably puts Lexaria way out in front of the nanotech boys in terms of convenience and cost, plus no sugar, no flavoring, no nanotech chemicals.
Plus later you'll probably be able to add ChargD+ nicotine to your drink so you don't have to go outside to smoke or vape anything. Going to be popular at airports. Big saving on shipping costs between a dozen bottles of cannabis-infused beverage and a dozen packs of powder!
Lexaria being left behind!
ORIGINAL: Joint Ventures are Leading the Cannabis Beverage Space into the Future; Sproutly Canada (CSE: SPR) (OTCQB: SRUTF), Hexo Corp., Canopy Growth
2018-11-13 10:00 ET - News Release
POINT ROBERTS, Wash., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks releases a sector snapshot with a focus on the recent JV’’s (joint ventures) and investments in the cannabis infused beverage market.
Why the urgency to invest and partner in the space? Multiple sources including Business Insider quoted recent market projections from Canaccord Genuity reporting,” Marijuana-infused beverages could become a $600 million market in the US in the next four years and big beverage makers are looking to take advantage of that opportunity.”
“Revenue from cannabis beverages could outpace the general demand for cannabis products by over two times, capturing 20% of the market for marijuana edibles by 2022, according to the analysts.”
Most recent JV news hitting the sector; Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) just announced that it has entered into a letter of intent with Global Canna Labs Limited, the Caribbean’s largest medical cannabis producer, to establish a joint venture for the purpose of developing, producing, distributing, marketing and selling cannabis infused beverages, edibles and topical products derived from Sproutly’s fully licensed, APP Technology.
From the news: “Partnering with Global Canna Labs on this joint venture allows Sproutly to expand its business outside of Canada with a leading, low cost cannabis cultivator in Jamaica that has proven distribution in across the Caribbean and expanding into the European Union,” said Keith Dolo, Chief Executive Officer and Director of Sproutly. “This partnership will enable Sproutly to diversify its product portfolio and accelerate its global distribution network from a low-cost regulated jurisdiction.”
Continued: “Paul Glavine, Chief Executive Officer of Global Canna Labs said, “We are eager to roll out this partnership with Sproutly on their APP technology. We have explored a number of options regarding extraction and cannabis technology solutions for beverage and derivative products – APP Technology is in our view the superior choice for beverage formulations. With our current supply and expansion plans to over 1 million square feet of cultivation, we see this partnership with Sproutly as a step towards utilization of our large-scale production towards a finished-product strategy.”
In early October, a substantial JV cannabis beverage announcement came from Molson Coors Canada (MCC), the Canadian business unit of Molson Coors Brewing Company, and HEXO Corp. (TSX: HEXO) (OTC:HYYDF). They reported the formation of a joint venture to pursue opportunities to develop non-alcoholic, cannabis-infused beverages for the Canadian market following legalization.
The joint venture, Truss, is led by former Molson Coors executive, Brett Vye, in the role of Chief Executive Officer. Vye reports to the Truss board of directors consisting of three members appointed by MCC and two members appointed by HEXO.
Mark Hunter, President and CEO of Molson Coors was quoted in an article earlier this month saying “clearly there are lots of numbers being bandied around with regard to the potential size of the cannabis market in Canada.” He went on to say, “I think, if you take the average, then it suggests that the market may be somewhere between $7 billion and $10 billion in market value, with beverages somewhere between 20% and 30%, and that’s obviously non-alcoholic cannabis infused beverages. Even if you take the low end of that estimate, then it suggests that the beverages segment could be circa $1.5 billion of value. We’re well placed to take a meaningful share of that segment.”
Not only are many companies looking to be the first to the beverage market, whether locally or internationally, but the consumer demand seems to be pushing that direction as well.
According to one survey, “76% of US and Canadian’s surveyed said they would use legal cannabis-infused products for therapeutic reasons, with nearly a quarter indicating that they'd try recreational cannabis via skincare products like lotions, creams and lip balms. 41% of the participants said they'd be more likely to try recreational cannabis through food, slightly higher than the 39% of those surveyed who said they would smoke it.”
There has been heavy investment into this concept, the largest example being the $5 Billion CAD [$4 Billion USD] investment from Constellation Brands into Canopy Growth Corp. (NYSE:CGC) (TSX:WEED), though speculation continues around Coca Cola’s interest in the Cannabis sector.
In a recent CBC article, Bruce Linton, the founder and co-CEO of Canopy Growth said ”new products developed by Tweed represent the next big opportunity.”
Continued: "I think if you're not preparing things two years in advance, you're never ready," he said. "Right now, none of the chocolate or gummy bears or beverages can be prepared or sold, but we're doing experiments on how to make them."
Walmart, much like Coca Cola, according New Frontier Data “has also led some investigation into the cannabis market for although Walmart does not sell CBD products, it does sell a variety of hemp-derived products; such as hemp oil, hemp soap, and hemp fiber.”
Continued: “At present, none of these large hemp companies sell CBD-related products, but look for some of them to start in 2019 as several leading brands look to expand their product offering into hemp-derived CBD to capitalize on mass market distribution opportunities. For now, all eyes are on the Farm Bill and FDA to give mass markets retailers, like Walmart, the green light to begin selling hemp products with CBD.”
As countries race to allow new legalization for cannabis, companies in the sector continue to push to be leading innovators. The next year offers the potential passing of the 2018 Farm Bill as well as the legalization of edibles and beverages in Canada on October 2019, which could see consumers very close to their first ‘cannabeverage’.
Investors can expect to see more money flow and JV’s as the sector ramps up.
Well, it's not a suppository, but ChargD+ could be added to your enema to help relieve the pain of a falling share price. Afterward, you can use the stock certificates to wipe your butt because they're not going to be worth a crap if Lexaria doesn't sign a licensing deal soon. Not one LP, big or small in all of North America seems interested in Lexaria's technology, nor do any major drink manufacturers. What's wrong here?
New product
http://grwellness.com/
That's it! I know what he's going to announce.
It's the DeydraTECH suppository.
The Bunka Butt Buster!
Yes hopefully, he's not blowing smoke or vapor up our butts.
The all-in-one.
It's a DehydraTECH pill with 10mg THC, 10mg CBD, 10mg NSAIDs, 10mg nicotine and 10mg Viagra.
What's he tweeting, I don't have twitter?
Delivery Systems
Symbol C : APH
Close 2018-11-01 C$ 15.15
Recent Sedar Documents
ORIGINAL: Innovative Cannabis Delivery Technologies on the Rise: The Greater Cannabis Company, Inc. (OTC: GCAN), Aphria, Tilray, Aurora and Canopy Growth
2018-11-02 07:30 ET - News Release
POINT ROBERTS, Wash. and KELOWNA, British Columbia, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks releases a sector snapshot with a focus on new and innovative delivery systems coming to market.
Through the month of September, larger Canadian cannabis companies including Aphria Inc. (TSX: APH), which commences trading on the NYSE today (NYSE:APHA), have been investing heavily in new cannabis delivery systems. These technologies have the ability to afford consumers a safer alternative to other routes of cannabinoid delivery, many of which have detrimental health effects.
The global trend is in play in the U.S. as well. This past Wednesday, The Greater Cannabis Company, Inc. (OTC: GCAN), a biopharmaceutical company focused on development and commercialization of innovative delivery systems for the Cannabis market, announced “the completion of development and reformulation of its eluting patch (EPP) for cannabinoid use. The EPP has been successfully developed in the past for pharmaceutical and over the counter (OTC) products, as well as for oral health applications. In preparation for commercializing cannabinoid products, the Company completed extensive testing of its new formulations. The cannabinoid transmucosal patch was found to have additional benefits over those previously mentioned, and which can be found on the Company’s website. GCAN’s product allows consumers to absorb cannabinoids through the vascular buccal mucosa (cheek) directly into the bloodstream, and bypass the GI tract. They look like Listerine fresh breath strips, but instead of melting in your mouth right away they have bioadhesive properties that allow the thin films to unobtrusively stick to the inside of your mouth. The cannabinoid actives loaded on the thin films absorb through the very vascular oral cavity and go right into the bloodstream. The unique delivery system also has a mechanism that allows for an initial rapid release of CBD/THC followed by a slow and gradual release of the cannabinoids on subsequent layers of the same thin film. The intent behind the fully dissolvable patch is to offer consumers a needle-free systemic delivery of cannabinoids, while effectively bypassing the digestive and hepatic systems, and without the side effects typically found with smoking or vaping.”
“The Company has entered into a new stage of aggressively ramping up its efforts to commercialize the technology through sublicensing and joint venture agreements. Target partners include licensed producers and dealers in the United States, Canada and abroad, as well as pharmaceutical companies focused on cannabinoids therapies.”
According to the company’s news – “New delivery systems are making their way into the industry. By way of example - the industry is fast adopting similar delivery technologies as seen in recent transactions.”
Standardized and controlled dosing is driving cannabis companies strategic direction, and what may been fueling many of these delivery system transactions. This new and innovative U.S. company (OTC: GCAN) is correct and right on the money in not only seeing the trend, but participating in it.
Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB.TO) announced it acquired an equity stake in CTT Pharmaceutical Holdings Inc. back in September of this year, converting the $1,000,000 USD/5% debenture into equity shares of CT, giving an approximate 9.14% equity ownership stake in CTT while still holding a warrant which enables Aurora to increase its equity ownership to 42.5%. CTT’s principal asset is a unique and novel patented drug delivery technology, an orally administered, fast-dissolving, thin film (the “Wafer”). This technology platform will target both the human and veterinary (pet) markets for treatment of many diseases. The Company believes that its Wafer technology will be one of the first to gain use in major markets such as pain management. Several Canadian and U.S. patents protect the Oral Thin Film (Wafer) formulation.
From the news, “CTT’s oral fast dissolving drug delivery systems consist of edible Wafers that dissolve without water and within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no smoke inhalation, less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is also improved especially with those who have a fear of choking or difficulty swallowing, and/or are pediatric, geriatric or incapacitated.”
Also in September, IntelGenx Corp. announced that it had executed a non-binding letter of intent with Tilray, Inc. (NASDAQ: TLRY) to co-develop and commercialize oral film products infused with recreational and medical cannabis (“cannabis-infused VersaFilm™”), in anticipation of amended cannabis regulations which would allow adult-use consumers to purchase edible products.
“Through the company’s work on VersaFilm with Tilray, IntelGenx Corp has also developed new products out of this technology, specifically RIZAPORT. The company recently announced that its commercialization partner for RIZAPORT® (10mg) in Spain, Groupo Juste, which is now part of Exceltis Healthcare, has received national marketing authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the product.”
“RIZAPORT® is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. RIZAPORT® offers an innovative and potentially advantageous therapeutic alternative for many migraine patients, primarily patients who suffer from dysphagia or migraine-related nausea, due to its convenient dosing, facile intake due to the lack of need for water, and neutral flavor.”
Continuing that same September delivery trend, CURE Pharmaceutical announced that “it entered into a multi-year licensing agreement for the first time with a leading international cannabis company, Canopy Growth (NYSE: CGC) (TSX: WEED.TO). Under the terms of the agreement, the cannabis company will have an exclusive license to CURE’s patented, multi-layer oral thin film (OTF) CUREfilm technology for use with cannabis extracts and biosynthetic cannabinoids in markets around the world.“
“Whole plant extracted, biosynthesized and synthetic cannabinoids all hold therapeutic promise for given indications and intended uses,” said Rob Davidson, CEO and chairman of CURE Pharmaceutical. “At CURE, we focus on synthetic cannabinoids for CUREfilm products, but with our new licensing business model, we will expand the impact and applications of our technology to these other promising approaches by partnering with an industry leader in this market.”
Aphria Inc. (TSX: APH) (NYSE: APHA) was no exception to the move of big cannabis companies buying into cannabis delivery systems. Aphria and Rapid Dose Therapeutics Inc., a Canadian bio-technology company focused on innovative drug delivery solutions, announced as well in September that they have “signed a non-binding Memorandum of Understanding related to RDT's QuickStrip™ products. Under the terms of the MOU, the companies intend to enter into a definitive agreement in the near future pursuant to which RDT will provide Aphria with exclusive global preferred rights to produce, distribute and sell QuickStrip™ products for cannabis markets around the world.”
According to their news, “Aphria is committed to bringing breakthrough innovations to the global cannabis market, which is why we are excited to introduce RDT as a strategic innovation partner,” said Jakob Ripshtein, Chief Commercial Officer at Aphria. “They have developed a truly innovative product that will offer both patients and consumers a new way to consume and experience cannabis. We eagerly anticipate launching QuickStrip™ delivery technology across our portfolio of medical and adult-use brands and look forward to extending this valuable partnership to other markets around the world.”
Seeing the amount of deal flow in the sector, the CEO is ramping up the roll-out for The Greater Cannabis Company, Inc. (OTC: GCAN). The Company’s sole focus now is to bring its licensed technology to market. “The technology has the ability to afford consumers a safer alternative to other routes of cannabinoid delivery, many of which have detrimental health effects. As part of its strategic initiative, the Company is seeking to expand its sales team with the intent to grow deal flow, and accelerate the sales cycle.”
Investor Ideas stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana/Hemp Stocks
About Investorideas.com - News that Inspires Big Investing Ideas
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this article featuring GCAN is a paid for article at Investorideas.com – learn more about costs and services https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Read Investorideas.com privacy policy:
Cannabis Social Media
Twitter
https://twitter.com/MJInvestorIdeas
Instagram
https://www.instagram.com/potcasts_investorideas/
Contact Investorideas.com
800-665-0411
I messaged Hill Street Beverages to find out what happened to their financing deal with a major LP.
"...a deal has not yet been signed, but discussions are ongoing."
What happened to Hill Street Beverages promise that they would sign a financing deal with a major LP by the end of October?
More BS?
Hopefully!
ORIGINAL: What’s Brewing in the Cannabis Beverage Market; American Premium Water (OTC: HIPH), Aurora Cannabis, Canopy Growth Corporation, The Hydropothecary Corporation
2018-10-22 08:00 ET - News Release
POINT ROBERTS, Wash. and DELTA, British Columbia, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks releases a sector snapshot with a focus on CBD and THC beverage deals brewing as the legal cannabis market in Canada just opened up new opportunities. Companies mentioned: American Premium Water Corporation (OTC: HIPH), Aurora Cannabis Inc. ( TSX: ACB.TO) ( OTC: ACBFF), Canopy Growth Corporation (TSX: WEED.TO), The Hydropothecary Corporation (TSX: HEXO.TO).
From announced deals of ‘Constellation Brands to Invest $5 Billion CAD [$4 Billion USD] in Canopy Growth to Establish Transformative Global Position and Alignment’, to speculative deals like the Aurora Cannabis Inc. (TSX: ACB.TO) (OTC: ACBFF) Coca-Cola deal, the amount of money at stake is staggering.
According to the news from Ontario based Canopy Growth Corporation (TSX: WEED.TO) (NYSE: CGC), commenting on the Constellation Brands deal, “This investment, the largest to date in the cannabis space, will provide funds which Canopy Growth will deploy to strategically build and/or acquire key assets needed to establish global scale in the nearly 30 countries pursuing a federally permissible medical cannabis program, while also rapidly laying the global foundation needed for new recreational cannabis markets. Canopy Growth's Canadian platform does not require additional cannabis cultivation assets, and management views other jurisdictions, including the United States, as strategic priorities requiring significant capital.”
In a recent Time.com article looking at the potential Coca-Cola /Aurora Cannabis Inc. (TSX: ACB.TO) (OTC: ACBFF) deal, it’s noted, “Coke’s possible foray into the marijuana sector comes as beverage makers are trying to add cannabis as a trendy ingredient while their traditional businesses slow.” The article also includes a statement from Coca-Cola; ‘“We are closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world,” Coca-Cola spokesman Kent Landers said in an emailed statement to Bloomberg News.’
Looking at why there is so much money being wagered on the cannabis beverage partnerships, the numbers in the industry tell the story. For example looking at the U.S. market alone, New Frontier Data says, “We forecast the legal cannabis market to grow to $25 billion by 2025 with a compound annual growth rate of 14.7%.” It’s no surprise then that the beer industry wants in when US Beer Sales Exceed $34 Billion in 2017. IRI Worldwide also notes in its report that, “Through December 31, U.S. beer volume sales decreased 0.4 percent while total beer dollar sales increased 1.2 percent.”
Looking at opportunities, both in the U.S and now in Canada, Ryan Fishoff, CEO of American Premium Water Corporation (OTC: HIPH) has ambitious plans for his cannabis beverage brand.
American Premium Water (OTC: HIPH) just announced on October 17th, “It has created a prototype tetrahydrocannabinol (THC)-infused beverage utilizing the Company’s hydro-nano technology, and that it is engaged in discussions with Canadian distributors and U.S. dispensaries. Upon official launch, American Premium expects to offer the first hydro-nano-infused THC beverage on the market.”
From the news – “With the legalization of cannabis in Canada, the Company is actively pursuing distribution agreements for both of its beverages in the Canadian market. The Company is also pursuing product distribution in U.S. states where Cannabis is legal, and is in discussions with dispensaries in California, Colorado, and Nevada.”
“Legalization in Canada and the development of our second beverage provides the opportunity for a distribution channel that not many of our competitors have. Additionally, we have a great geographic advantage in the U.S. I am based in New York City, our Chairman is located in Miami, and our headquarters are in Los Angeles – meaning we have ‘boots on the ground’ footholds in the country’s largest and most visible markets. With the addition of the THC prototype, we are going to exploit this advantage and ramp up our marketing activities in these regions. An example of something that I have in mind is doing a pop up with MedMen’s New York location. Doing a pop up with them (MedMen) would be an example of the type of marketing events that we intend to rollout in the coming months to take advantage of our geographic advantage. Over the ensuing weeks, I will share in more detail our wholesale distribution strategy for both the CBD and THC beverages,” stated Fishoff.
Following his news, one of American Premium Water distributors SinglePoint Inc., announced a successful first week of sales of the newly listed product, Lalpina CBD Water.
Also entering the THC beverage market, Lagunitas Brewing Company, a subsidiary of Heineken International, announced in late June its launch of Hi-Fi Hops. “This IPA-inspired sparkling water is made using everything Lagunitas knows about hops and is infused with THC and/or CBD (depending on your vibe). This new beverage collaboration with AbsoluteXtracts is yet another example of Lagunitas’ creativity at the intersection of culture, marijuana and craft beer, and marks the first time a major brewery has successfully and legally been represented in the THC-infused beverage space. At its core, Hi-Fi Hops is inspired by our IPA, tastes as refreshing as water (yeah, no calories or carbs!) and gives you the chill of sun-grown cannabis from AbsoluteXtracts, a CannaCraft brand.”
“Hi-Fi Hops is not the first chapter in the love affair between cannabis and Lagunitas, but it is one of the most exciting,” said Maria Stipp, CEO of Lagunitas Brewing Company. “The idea of being a part of a no-calorie beverage infused with cannabis seemed like a perfect next step in our product innovation, and a natural way to marry our past with our future.”
And the beverage deals continued to flow; On August 1st, Molson Coors Canada, the Canadian business unit of Molson Coors Brewing Company and Canadian cannabis producer, The Hydropothecary Corporation (TSX: HEXO.TO) announced that they have entered into a definitive agreement to form a joint venture to pursue opportunities to develop non-alcoholic, cannabis-infused beverages for the Canadian market following legalization.
From the Molson news - “Canada is breaking new ground in the cannabis sector and, as one of the country’s leading beverage companies, Molson Coors Canada has a unique opportunity to participate in this exciting and rapidly expanding consumer segment. This new venture is consistent with our growth strategy and our commitment to being First Choice for Consumers and Customers by ensuring that Canadians have access to high-quality products that meet their evolving drinking preferences,” said Frederic Landtmeters, President and CEO of Molson Coors Canada. “While we remain a beer business at our core, we are excited to create a separate new venture with a trusted partner that will be a market leader in offering Canadian consumers new experiences with quality, reliable and consistent non-alcoholic, cannabis-infused beverages. We look forward to partnering with HEXO, a recognized leader in the medical cannabis space in Canada that will bring robust production capacity, a track record of innovation, and, most importantly, shared values when it comes to doing business the right way and earning the trust of consumers.”
How will the cannabis beverage marriage play out in Canada? According to an article on CBC, "Canadians could soon be spending more on recreational cannabis than they do on liquor, if a report from a major bank is to be believed. Canadian Imperial Bank of Commerce calculated in a report this week that in the next two years, Canadians will consume 800,000 kilograms of cannabis, the vast majority of which will be for recreational use."
So the marriage of cannabis and beverages combined will make a significant splash in Canada and globally as it rolls out. Cheers to that!
Investor Ideas stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana/Hemp Stocks
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Sign up to get the news alerts including the daily podcast and transcript for Investor ideas podcasts
Hear Investor ideas cannabis potcast on iTunes
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts, articles, podcasts and videos talking about cannabis, crypto, technology including AI and IoT, mining, sports biotech, water, renewable energy and more. Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the Stock Guru daily podcast on Support and Resistance Trading.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this article featuring HIPH is a paid for article (third party) at Investorideas.com – learn more about costs and services https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Po
Ebbu uses nano-technology for their HydroPS cannabis infusion technology. What do they use for the emulsifier? A chemical or is it natural? No one knows!
https://extractionmagazine.com/category/applied-technology/ebbu-hydrops-system-soluble-cannabinoids/
After reading about Ebbu tech. for infusing beverages, I'd say that it's inferior to Lexaria's as they haven't solved the taste problem. Rebel Coast uses Ebbu's tech to infuse only 16 mg into each bottle of wine, yet the wine still tastes of cannabis! Also, Ebbu has no patents awarded, 40 patents are pending.
"Rebel Coast tastes slightly of cannabis, but the goal is to make it a premium bottle of sauvignon blanc."
https://www.laweekly.com/restaurants/rebel-coasts-sauvignon-blanc-will-get-you-high-not-drunk-9019324
"The science behind the process of infusing cannabidiol or other cannabis ingredients into beverages is an extremely difficult one, he said."
https://www.benzinga.com/analyst-ratings/analyst-color/18/10/12527963/why-you-should-be-careful-with-these-cannabis-infused-b?fbclid=IwAR0CVcd-EWwyfD4ZDgEks9uSESntre46devck0-Q3M2B1Hbzl8UMklGvaOU
The Next Catalyst
Hill Street Beverages president Terry Donnelly recently stated that he expected to announce a funding deal with a major LP by the end of the month.
We know it's not going to be Canopy as they just took over Ebbu and gained their infusion tech, so that leaves probably either Aurora or Aphria or perhaps Tilray.
My money is on Aurora, once they establish a presence in the infused beverage industry through BEER and LXRP, then the big money will flow in, Altria?
Whoever it is, Lexaria will gain instant recognition and validation.
One thing you can count is there is going to be a lot of consolidation and large investments in the cannabis market.
Does Ebbu have a better Tech. than Lexaria or are they comparable?
https://seekingalpha.com/article/4212795-cisco-pot-makes-another-key-purchase